SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Stem Cell Research -- Ignore unavailable to you. Want to Upgrade?


To: SnowShredder who wrote (126)7/13/2005 12:21:26 PM
From: keokalani'nui  Respond to of 495
 
World's Oldest, Largest Organization of Cancer Scientists Favors 'Full Spectrum of Stem Cell Biology'
Wednesday July 13, 11:41 am ET
AACR Supports Stem Cell Research to Prevent, Diagnose and Treat Cancer

PHILADELPHIA, July 13 /PRNewswire/ -- Stem cell research -- including research involving human embryonic stem cells -- is essential to the advancement of cancer research, according to a position statement adopted by the Board of Directors of the American Association for Cancer Research.
"As the community of scientists on the front lines of the battle against cancer, we are firm in our belief that continued experimentation with human stem cells is necessary to improve evaluation of anti-cancer drugs, to identify markers for early detection of cancer, and to illuminate the path to novel, targeted treatments," said Lynn M. Matrisian, Ph.D., AACR past president and Ingram Distinguished Professor of Cancer Research at Vanderbilt University in Nashville, Tenn.

"Our belief is based on the results of peer-reviewed research, the strength of professional integrity and long-standing ethical principles, and profound respect for human life," added Matrisian, who also is professor and chair of the department of cancer biology at Vanderbilt.

The association's statement is equally vehement in its rejection of any technology, including stem cell technology, used in human reproductive cloning, noting that, "such attempts have no beneficial goal and can be reasonably assumed to cause harm." At the same time, the AACR position supports the "ethical use of somatic cell nuclear transfer," noting that the technique, "promises to reveal the role of specific genetic alterations in tumorigenesis and further refine evaluations of drug activity, as well as generate immune-compatible material for transplant therapies."

The primary points of the AACR position on stem cell biology are:

* Human stem cell research will elucidate critical aspects of cell growth
and differentiation that are altered during the formation and growth of
tumors.

* Research on tissue-specific stem cells from adults may reveal the body's
innate maintenance and repair mechanisms.

* Embryonic stem cells have the ability to transform into the cells of
every major organ system in the human body. If this characteristic can
be controlled, then medical researchers could determine the signals that
direct the development of human tissues, including cancers.

* Bone marrow stem cells already have demonstrated their value in
replenishing blood and immune systems damaged by cancer or cancer
treatment. Research on human embryonic stem cells may extend this
promise by providing a transplantable cell source that avoids the
problems of immune rejection.

* Cancer stem cells have been described as the progenitors of breast,
prostate, brain and other malignant tumors, raising the prospect of
eliminating tumor recurrence following initial treatment and developing
cancer therapies that are truly curative.

* Embryonic stem cells' ability spontaneously to form tumors should not
hinder the progress of stem cell research, since these cells will be
used only as precursors to the differentiated cells needed to replenish
damaged tissue.

In light of the recent cloning of patient-specific human embryonic stem cells by researchers in South Korea, AACR Science Policy and Legislative Affairs Committee Chairman William G. Nelson V, M.D., Ph.D., pointed to the clause in the AACR position statement encouraging grant-making institutions to "work toward stable and sufficient funding for meritorious stem cell projects, free of political uncertainty, so that young investigators are encouraged to devote their careers to this important field."

Said Nelson, professor in the departments of Oncology, Urology, Pharmacology and Molecular Sciences, Medicine, Pathology, and Radiation Oncology and Molecular Radiation Sciences, at Johns Hopkins University, "The United States is so closely associated with scientific advancements that the first question on everyone's mind was, 'why wasn't this huge medical breakthrough made by Americans?'

"Sadly," he continued, "American stem cell biology suffers from a small and unsteady flow of graduate students, post-doctoral fellows and early-career faculty. No scientific discipline can grow without the constant infusion of new talent and new ideas."

Founded in 1907, the American Association for Cancer Research is a professional society of more than 24,000 laboratory, translational, and clinical scientists engaged in all areas of cancer research in the United States and in more than 60 other countries. AACR's mission is to accelerate the prevention and cure of cancer through research, education, communication, and advocacy. Its principal activities include the publication of five major peer-reviewed scientific journals: Cancer Research; Clinical Cancer Research; Molecular Cancer Therapeutics; Molecular Cancer Research; and Cancer Epidemiology, Biomarkers & Prevention. AACR's Annual Meetings attract more than 16,000 participants who share new and significant discoveries in the cancer field. Specialty meetings, held throughout the year, focus on the latest developments in all areas of cancer research.

CONTACT: Elizabeth Tait of the American Association for Cancer Research, +1-215-440-9300, ext. 144, or tait@aacr.org.



To: SnowShredder who wrote (126)7/22/2005 3:56:12 PM
From: SnowShredder  Read Replies (1) | Respond to of 495
 
Evidence boosts stem cells' promise
With patient's own cells, heart vessels and tissue show mending


Just parking...

Best of Luck,

SS

chron.com

>>>>

July 21, 2005, 11:49PM

Evidence boosts stem cells' promise
With patient's own cells, heart vessels and tissue show mending
By TODD ACKERMAN
Copyright 2005 Houston Chronicle

RESOURCES
HELPING TO FIX A DAMAGED HEART

How the cells are injected:
• Extraction: Surgeons insert a needle into the patient's hip bone to extract 50 cubic centimeters of bone-marrow cells.
• Process: The cells are processed in the laboratory for about three hours to cull stem cells.
• Catheterization: The stem cells are immediately taken to a catheterization lab where the same patient is ready for surgery.
• Map: With a special catheter, surgeons electrically map the heart to identify damaged areas.
• Injection: After selecting 15 areas, they inject 2 million cells into surrounding healthy tissue.
• Recovery: Patients leave the hospital the next day. Improvement in health may begin within six weeks.

The Heart Institute's ongoing study is now open to patients with severe heart failure from outside Houston. To be considered, patients should call 832-355-6555, or e-mail their information to stemcell@heart.thi.tmc.edu
Local scientists are reporting new evidence of the effectiveness of treating congestive heart failure with a patient's own stem cells.

In a postmortem examination of a trial participant who died of an unrelated condition 11 months after receiving the therapy, the researchers found stem cells injected directly into the heart not only improved blood flow and blood-vessel formation but even grew new tissue.

"This is the first time we've achieved clear documentation of these effects in a human heart," said Dr. James Willerson, medical director of the Texas Heart Institute at St. Luke's Episcopal Hospital, which is leading the research. "We're trying to stay cautious, but this is very exciting."

Previously, imaging procedures had provided evidence of the therapy's effectiveness in patients. Such evidence, however, is not considered as definitive as evidence from the actual organ.

The therapy, unthinkable less than a decade ago, is particularly hailed in some circles because adult stem cells don't pose the ethical concerns embryonic stem cells do. Embryonic stem cells, considered more versatile, require the destruction of the embryo.

A paper describing the Texas Heart Institute researchers' findings with the deceased patient will be published in the July 26 edition of Circulation, the American Heart Association's journal. It was made available on the journal's Web site this week.

The patient, a 55-year-old Brazilian man who'd previously had two heart attacks, was part of a clinical trial begun four years ago on people with end-stage heart failure. That trial, a collaboration between researchers at the Texas Heart Institute and Pro-Cardiaco Hospital in Rio de Janeiro, showed improved heart function in all patients who received the injection of stem cells taken from their bone marrow.

Human trials ongoing
The results led the Food and Drug Administration last year to approve the first human trial in the United States, currently ongoing at the heart institute. There are no results from the trial yet, but Willerson said it is going well.

The postmortem exam found the Brazilian's heart showed an increase in blood vessels in the area injected with stem cells as well as the presence of substances that indicate cellular regeneration. The man died of a stroke caused by a neurological problem.

The treatment involves using a special catheter threaded through the groin. Doctors use an innovative mapping technology to identify areas in the heart that have sustained mechanical and electrical damage, then inject millions of stem cells directly into the left ventricle along the periphery of the damaged area.

The ongoing study at the heart institute was at one time limited to patients in the greater Houston area but is now open to other patients with severe heart failure. In all, 30 patients will participate — 20 receiving the treatment and 10 acting as a control group. Those who don't receive the treatment will have the option to do so after six months of evaluation.

Three more trials are planned. One will be in Spain; one will be a collaboration between the heart institute and an unnamed institution in the southeastern United States; and one, at the heart institute, will enroll patients with coronary heart disease but not heart failure who are waiting for transplants.

Looking toward future

Though the therapy is still in the early stages of research, Willerson said if the results continue to be positive, the team could ask the FDA for treatment approval in as little as three years. He said follow-up trials still need to determine the best patients, stem-cell types and ways to deliver the therapy.

Coronary heart disease — insufficient blood flow to the heart — affects more than 12 million Americans and is the nation's leading cause of death. Stem-cell therapy, if successful, could offer hope for patients in the end stages of the disease as well as those who undergo angioplasty and bypass surgery for cases that can't be treated with medicine.

"It's pretty amazing," Willerson, president-elect of the heart institute and president of the University of Texas Health Science Center at Houston, said of the recently unsuspected therapeutic ability of adult stem cells. "Five years ago, if I'd asked cell biologists about treating patients with heart failure with adult stem cells, I think I'd be in an insane asylum."

todd.ackerman@chron.com